EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Evaluation of treatment response to generic imatinib in newly diagnosed low-risk Ph+ CML patients

Dr. Muhammad Fahad Akbar, Dr Muhammad Tahir, Dr. Rizwan Munir

Anaesthesia, Pain & Intensive Care · 2026-10-04 · 30 (7)

DOI: 10.35975/apic.v30i7.3305 ↗
AbstractBibliografische Angaben

Abstract

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder driven by the BCR-ABL fusion gene. Imatinib, a first-generation tyrosine kinase inhibitor, remains the standard first-line therapy. Objective: To evaluate the treatment response to generic imatinib in newly diagnosed low-risk Philadelphia chromosome-positive CML patients. Methodology: This quasi-experimental study was conducted at the Department of Oncology, Allied Hospital Faisalabad, from February 2025 to March 2026. A total of 174 patients were enrolled using non-probability consecutive sampling. Eligible patients were newly diagnosed, untreated low-risk Ph+ CML cases aged 18–60 years. All patients received generic imatinib at a dose of 300 mg twice daily. Baseline and three-month assessments included complete blood counts and quantitative BCR-ABL PCR. Results: The mean age of patients was 38.6 ± 10.2 years, with 58.0% males. CHR was achieved in 85.6% of patients. Complete cytogenetic response was observed in 69.5%, while 29.9% achieved MMR at three months. There was a significant reduction in mean BCR-ABL levels from 78.4 ± 12.6% at baseline to 6.2 ± 3.8% at three months (p < 0.001). Significant associations with CHR were observed for age (p=0.041), gender (p=0.032), splenomegaly (p=0.018), and treatment compliance (p < 0.001). Most patients experienced no or mild adverse effects. Conclusion: Generic imatinib is an effective, safe, and well-tolerated treatment option in newly diagnosed low-risk Ph+ CML patients, demonstrating high early response rates and significant molecular reduction, with treatment adherence playing a critical role in achieving optimal outcomes. Keywords: Chronic myeloid leukemia, Imatinib, Generic drugs, BCR-ABL, Hematologic response, Molecular response Citation: Akbar MF, Tahir M, Munir R. Evaluation of Treatment Response to Generic Imatinib in Newly DiagnosedLow-Risk Ph+ CML Patients. Anaesth. pain intensive care 2026;30(7). DOI: 10.35975/apic.v30i7.3305 Received: March 31, 2026 ; Revised: xxxxxxxx; Accepted: May 04, 2026

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →